Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing
Reexamination Certificate
2005-05-24
2005-05-24
Andres, Janet (Department: 1647)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
C435S007100, C530S350000, C530S387100
Reexamination Certificate
active
06896872
ABSTRACT:
A methods, kits and compositions for diagnosing a central nervous system disorder, particularly transient ischemic attack or stroke, comprising measuring the level of NR2A and/or NR2B NMDA receptor or fragment thereof, in a biological sample from a human subject, and optionally measuring other biomarkers such as homocysteine and glutamate. The method is particularly useful for identifying individuals that are at risk for stroke, and for diagnosing stroke in an emergency room setting.
REFERENCES:
patent: 5849895 (1998-12-01), Daggett et al.
patent: 6316611 (2001-11-01), Daggett et al.
Senju et al. (1986), A new immuno quantitative method by latex agglutination—application for the determination of serum C-reactive protein (CRP) and its clinical significance, J. Clin. Lab. Immunol. 19(2): 99-103.*
Pang et al. (1988), Early diagnosis of acute myocardial infarction by myoglobin latex agglutination test, Jpn. Heart J. 29(5):631-638.*
Gray et al. (1987), Evaluation of a commercial latex agglutination test for detecting antibodies to cytomegalovirus in organ donors and transplant recipients, J. Virol. Meth. 16(1-2): 13-19.*
Gusev et al.; “Investigation of the Level of Autoantibodies to Glutamate Receptors in Blood Serum of Patients in Acute Period of Ischemic Stroke;” Zhurnal Nevrologii I Psikhiatrii Imeni S. S. Korsakova; vol. 96, No. 5; 1996; pp. 68-72; XP002212398; Abstract.
Hess et al.; “Cloning and Functional Characterization of Human Heteromeric N-Methyl-D-Aspartate Receptors;” Journal of Pharmacology and Experimental Therapeutics, American Society for Pharmacology and, US, vol. 278; No. 2; Aug. 1, 1996; pp. 808-816; XP000676640; ISSN: 0022-3565; Abstract.
Monyer et al.; “Heteromeric NMDA Receptors: Molecular and Functional Distinction of Subtypes;” Science; May 22, 1992; vol. 256; No. 5060; pp. 1217-1221; ISSN: 0036-8075; XP001093645; Abstract.
Skoromets et al.; “Autoantibodies to NMDA-receptor fragments in patents with ischemic stroke;” Journal of the Neurological Sciences; vol. 150; (1997); p. S280; XP001098449; Abstract.
Dambinova, et al., “Autoantibodies to Subtypes of Glutamate Receptors as a Hallmarks of Brain Damage: Diagnostic Significance for Paroxysmal Activity and Ischemia.”Journal of Higher Nervous Activity.1997. vol. 47 (2), pp. 151-156.
Gusev, et al., “Neuroprotective Effects of Glycine for Therapy of Acute Ischaemic Stroke.”Cerebrovasc Dis 2000; 10:49-60.
Gahring, et al., Autoantibodies to Neuronal Glutamate Receptors in Patients with Paraneoplastic Neurodegenerative Syndrome Enhance Receptor Activation.Molecular Medicine, vol. 1, No. 3, Mar. 1995, 245-253.
Rogers, S.W., “Autoantibodies to Glutamate Receptor GluR3 in Rasmussen's Encephalitis.”Ovid: Science, vol. 265(5172), Jul. 29, 1994, pp. 648-651.
Dambinova, et al., “Monitoring of Brain Spiking Activity and Autoantibodies to N-Terminus Domain of GluR1 Subunit of AMPA Receptors in Blood Serum of Rats with Cobalt-Induced Epilepsy.”Journal of Neurochemistry, Lippincott-Raven Publishers, Philadelphia.
Dambinova, et al., “The presence of autoantibodies to N-terminus domain of GluR1 subunit of AMPA receptor in the blood serum of patients with epilepsy.”Journal of Neurological Sciences, 152 (1997), 93-97.
Vincent, et al., “Pathogenic autoantibodies to neuronal proteins in neurological disorders.”Journal of Neuroimmunology, 100 (1999) 169-180.
Lipton, et al., Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor.Proc. Natl. Acad. Sci. USA, vol. 94, pp. 5923-5928, May 1997.
Meldrum, B.S., “Glutamate as a Neurotransmitter in the Brain: Review of Physiology and Pathology1.”Journal of Nutrition, 2000; 130:1007S-1015S.
Dávalos, et al., “Neurological Deterioration in Acute Ischemic Stroke: Potential Predictors and Associated Factors in the European Cooperative Acute Stroke Study (ECASS) 1.”Ovid: Davalos: Stroke, vol. 30(12), Dec. 1999, 2631-2636.
Davalos, et al., “Duration of Glutamate Release After Acute Ischemic Stroke.”Ovid: Davalos: Stroke, vol. 28(4), Apr. 1997, 708-710.
Castillo, et al., “Neuroexcitatory Amino Acids and Their Relation to Infarct Size and Neurological Deficit in Ischemic Stroke.”Ovid: Castillo: Stroke, vol. 27(6), Jun. 1996, 1060-1065.
Yamamoto, et al., “CSF and ECF Gluatmate Concentrations in Head Injured Patients.”Acta Neurochir(1999) [Suppl] 75:17-19.
Castillo, et al., “Progression of ischaemic stroke and excitotoxic aminoacids.”Lancet1997; 349: 79-83.
Gusev, et al., “The level of autoantibodies to glutamate receptors in the blood serum of patients in the acute period of ischemic stroke.”Ovid Technologies. Inc., 2000-2001, Version re14.5.0, SourceID 1.5686.1.73. (Abstract).
Vila, et al., “Plasma homocysteine levels in patients with ischemic cerebral infarction.”Med Clin(Barc) May 9, 1998; 110(16): 605-8. (Abstract).
Hill, et al., “Biochemical markers in acute ischemic stroke.”Canadian Medical Association Journal, Apr. 18, 2000; 162:1139-40.
Andres Janet
Hunnicutt Rachel K.
King & Spalding
Sullivan Clark G.
LandOfFree
Rapid multiple panel of biomarkers in laboratory blood tests... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Rapid multiple panel of biomarkers in laboratory blood tests..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Rapid multiple panel of biomarkers in laboratory blood tests... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3446469